PERSONALIS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.245 USD | +2.89% |
|
-3.72% | -41.54% |
Chart calendar Personalis, Inc.
d5d2ad9cbf.aVQKBUSQIdMS7sBWW8VBcQmZ5rdGrlP2Vxi5VHkx6ek.MQxwdCL1dYV-2bAHEb0TE0DJoucZ_zW4GkfPYhVWm9oneWUzFuNH_mjf9A~39da1ffa0cab724bc5085531411e8dde
Upcoming events on Personalis, Inc.
Past events on Personalis, Inc.
| 2024-04-10 01:30 pm | Needham Healthcare Conference |
| 2024-04-09 05:55 pm | American Association for Cancer Research Meeting |
| 2024-04-09 04:30 pm | American Association for Cancer Research Meeting - Abstract No:6094 |
| 2024-04-09 12:00 pm | American Association for Cancer Research Meeting - Abstract No:5034 |
| 2024-04-07 04:30 pm | American Association for Cancer Research Meeting - Abstract No:976 |
| 2024-03-06 12:50 pm | TD Cowen Health Care Conference |
| 2024-02-28 05:00 pm | Q4 2023 Earnings Call |
| 2024-02-28 04:01 pm | Q4 2023 Earnings Release |
| 2024-02-12 | BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
| 2023-11-07 05:00 pm | Q3 2023 Earnings Call |
| 2023-11-07 04:01 pm | Q3 2023 Earnings Release |
| 2023-10-24 09:00 am | Business Update Call |
| 2023-10-21 04:15 am | European Society for Medical Oncology Congress - Presentation #LBA55 |
| 2023-09-12 04:55 pm | Morgan Stanley Global Healthcare Conference |
| 2023-08-16 12:15 pm | Sidoti Virtual Micro Cap Conference |
| 2023-08-13 | Needham Virtual MedTech & Diagnostics Conference |
| 2023-08-08 05:00 pm | Q2 2023 Earnings Call |
| 2023-08-08 04:01 pm | Q2 2023 Earnings Release |
| 2023-06-01 | American Society of Clinical Oncology Conference - Association of ultra-sensitive ctDNA |
| 2023-06-01 | American Society of Clinical Oncology Conference - Ultra-sensitive, tumor-informed ctDNA |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 65,2 64,9 0.48% | 78,6 78,4 0.28% | 85,5 85,5 -0% | 65,0 64,6 0.77% | 73,5 73,2 0.41% | 74,1 |
|
EBITDA Million USD | Released Forecast Spread | -17,7 -18,7 5.58% | -36,4 -33,2 -9.58% | -59,3 -59,2 -0.18% | -107 -101 -6.08% | -98,6 -95,7 -3.07% | -77,0 |
|
EBIT Million USD | Released Forecast Spread | -22,4 -22,8 1.59% | -42,1 -39,7 -6.19% | -65,4 -67,8 3.58% | -116 -113 -2.06% | -110 -111 1.21% | -80,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -25,1 -26,7 6.09% | -41,2 -38,7 -6.48% | -65,2 -67,4 3.21% | -113 -112 -1.27% | -108 -106 -2.26% | -77,1 |
|
Net income Million USD | Released Forecast Spread | -25,1 -27,4 8.45% | -41,3 -39,1 -5.71% | -65,2 -67,5 3.39% | -113 -112 -1.27% | -108 -106 -2.37% | -77,2 |
|
EPS USD | Released Forecast Spread | -1,39 -1,11 -25.23% | -1,20 -1,16 -3.75% | -1,49 -1,53 2.72% | -2,48 -2,45 -1.43% | -2,25 -2,21 -1.72% | -1,58 |
| Announcement Date | 25/03/20 | 25/02/21 | 24/02/22 | 23/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 20,7 20,7 -0.05% | 15,2 14,4 5.6% | 18,2 15,5 17.63% | 14,9 13,6 8.96% | 16,7 16,3 2.9% | 18,9 17,4 8.7% | 16,7 16,5 1.24% | 18,2 17,0 7.47% | 19,8 19,3 2.34% | 18,3 | 18,5 | 18,9 | 18,5 | 16,1 |
|
EBITDA Million USD | Released Forecast Spread | -18,6 -19,8 6.04% | -26,5 -24,5 -8.33% | -26,1 -25,3 -3% | -25,4 -26,8 5.28% | -29,1 -25,9 -12.68% | -27,0 -20,5 -31.92% | -22,5 -19,8 -13.62% | -22,5 -18,2 -23.46% | -21,1 -20,1 -5.06% | -20,1 | -16,3 | -15,0 | -16,1 | |
|
EBIT Million USD | Released Forecast Spread | -20,2 -22,6 10.42% | -28,3 -27,0 -4.78% | -27,9 -28,4 1.9% | -27,3 -29,7 8.34% | -32,1 -29,8 -7.8% | -29,8 -26,3 -13.4% | -25,3 -25,6 1.16% | -25,2 -26,1 3.21% | -24,0 -24,4 1.7% | -19,8 | -19,4 | -19,6 | -20,0 | -21,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -20,2 -22,2 9.06% | -28,2 -28,0 -0.72% | -27,5 -28,4 3.14% | -26,5 -29,9 11.53% | -31,1 -29,6 -5.06% | -28,6 -25,7 -11.68% | -23,9 -25,1 4.58% | -29,1 -25,1 -15.68% | -26,6 -23,2 -14.76% | -19,1 | -18,7 | -19,0 | -19,5 | -20,3 |
|
Net income Million USD | Released Forecast Spread | -20,2 -22,4 9.98% | -28,2 -26,9 -4.89% | -27,5 -28,3 2.6% | -26,5 -29,5 10.08% | -31,1 -29,6 -5.09% | -28,7 -25,7 -11.73% | -24,0 -25,1 4.44% | -29,1 -25,2 -15.63% | -26,6 -23,2 -14.78% | -19,1 | -18,7 | -19,0 | -19,5 | -20,3 |
|
EPS USD | Released Forecast Spread | -0,45 -0,50 9.4% | -0,63 -0,60 -5.7% | -0,60 -0,63 4.15% | -0,58 -0,64 9.09% | -0,67 -0,64 -5.1% | -0,61 -0,56 -9.91% | -0,50 -0,54 6.54% | -0,60 -0,52 -14.83% | -0,54 -0,50 -8% | -0,41 | -0,39 | -0,39 | -0,39 | -0,39 |
| Announcement Date | 24/02/22 | 04/05/22 | 03/08/22 | 02/11/22 | 23/02/23 | 03/05/23 | 08/08/23 | 07/11/23 | 28/02/24 | - | - | - | - | - |
More events
Past sector events for Personalis, Inc.
| 2024-04-17 | HINOVA PHARMACEUTICALS INC.: Q4 2023 Earnings Release |
| 2024-04-17 02:07 am | TELIX PHARMACEUTICALS LIMITED: March 2024 Sales and Revenue Release - Activities Report |
| 2024-04-10 04:10 pm | PHARVARIS N.V.: Q4 2023 Earnings Release |
| 2024-04-10 01:22 am | POLARIS GROUP: March 2024 Sales and Revenue Release |
| 2024-04-02 02:30 am | ABIVAX: Q4 2023 Earnings Release |
| 2024-04-01 09:00 am | BIOMEA FUSION, INC.: Q4 2023 Earnings Release |
| 2024-03-28 10:42 pm | ALPHAMAB ONCOLOGY: Q4 2023 Earnings Release |
| 2024-03-28 04:28 pm | CENTESSA PHARMACEUTICALS PLC: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ARRIVENT BIOPHARMA, INC.: Q4 2023 Earnings Release |
| 2024-03-28 07:10 am | HANGZHOU TIGERMED CONSULTING CO., LTD: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- PSNL Stock
- Calendar Personalis, Inc.
